GH Research PLC
GH Research PLC (GHRS) Historical Volatility
GHRS's 30 day historical volatility is 54.29%, in the 25th percentile of readings over the past year. This is a low percentile, meaning GH Research PLC shares have been calmer than usual. GHRS's 30 day implied volatility sits at 114.65%, with an IV Rank of 63.10%, leaving IV 60.36 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.
Read more
Tracking GHRS historical volatility helps you see how much GH Research PLC's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, GHRS's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor GHRS 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. GHRS's 30 day historical volatility, or GHRS HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing GHRS's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders.
Historical Volatility
Historical movement is subdued versus the past year. The stock has been unusually quiet.
As of Nov 18, 2026
As of Nov 18, 2026
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →